| Malawi | Uganda | Zimbabwe | |||||
---|---|---|---|---|---|---|---|---|
 | Primary | Secondary | Tertiary | Primary | Secondary | Tertiary | Primary | Secondary |
 | (n = 16) | (n = 3) | (n = 1) | (n = 21) | (n = 16) | (n = 2) | (n = 16) | (n = 6) |
Antibiotics | ||||||||
No. facilities with stock-outs | 5/16 | 1/3 | 0/1 | 17/21 | 6/16 | 2/2 | 4/16 | 0/6 |
No. days/90 per facility if >0 | 14,14,30,60,60 | 30 | Â | 14,14,14,21,30,30,30,30,35,42,59,60,60,60,70,75,90 | 7,10,14,21,28,30 | 14,30 | 5,7,90,90 | Â |
TB drugs | ||||||||
No. facilities with stock-outs | 1/16 | 1/3 | 0/1 | 9/17 | 2/16 | 1/2 | 2/14 | 1/6 |
No. days/90 per facility if >0 | 2 | 30 | Â | 7,14,14,15,30,31,60,60,90 | 31,90 | 30 | 3,60 | 14 |
Anti-malarial drugs | ||||||||
No. facilities with stock-outs | 2/16 | 0/3 | 0/1 | 3/21 | 2/16 | 0/2 | 1/16 | 0/6 |
No. days/90 per facility if >0 | 5,7 | Â | Â | 14,14,14 | 21,30 | Â | 7 | Â |
HIV test kits | ||||||||
No. facilities with stock-outs | 10/16 | 1/3 | 0/1 | 5/21 | 4/16 | 1/2 | 2/16 | 0/6 |
No. days/90 per facility if >0 | 3,8,14,14,14, 18,23,25,30, 30 | Days missing | Â | 3,14,30,30,30 | 5,7,21,90 | 1 | 4,7 | Â |
Cotrimoxazole for HIV positive patients | ||||||||
No. facilities with stock-outs | 11/15 | 0/3 | 0/1 | 8/19 | 4/16 | 0/2 | 1/16 | 1/6 |
No. days/90 per facility if >0 | 14,21,31,45,60,60,66,70,90,90,90 | Â | Â | 20,21,60,60,66,90,90,90 | 28,30,60,90 | Â | 7 | 90 |
ART for PMTCT | ||||||||
No. facilities with stock-outs | 2/15 | 2/3 | 1/1 | 3/21 | 1/16 | 0/2 | 0/16 | 0/6 |
No. days/90 per facility if >0 | 14,60 | 7,90 | 62 | 2,14,60 | 31 | Â | Â | Â |
Adult ART | ||||||||
No. facilities with stock-outs | 0/9 | 1/3 | 0/1 | 0/6 | 0/16 | 0/2 | 1/1 | 1/6 |
No. days/90 per facility if >0 | Â | 30 | Â | Â | Â | Â | 30 | 14 |
Paediatric ART | ||||||||
No. facilities with stock-outs | 2/9 | 0/3 | 0/1 | 3/6 | 3/16 | 0/2 | Â | 2/6 |
No. days/90 per facility if >0 | 1,7 | Â | Â | 14,90,90 | 14,30,60 | Â | Â | 14,40 |